[go: up one dir, main page]

CA2309395A1 - Methodes de prevention et de traitement de la maladie d'alzheimer - Google Patents

Methodes de prevention et de traitement de la maladie d'alzheimer Download PDF

Info

Publication number
CA2309395A1
CA2309395A1 CA002309395A CA2309395A CA2309395A1 CA 2309395 A1 CA2309395 A1 CA 2309395A1 CA 002309395 A CA002309395 A CA 002309395A CA 2309395 A CA2309395 A CA 2309395A CA 2309395 A1 CA2309395 A1 CA 2309395A1
Authority
CA
Canada
Prior art keywords
fsh
agent
disease
gnrh
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002309395A
Other languages
English (en)
Inventor
Richard Lloyd Bowen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voyager Pharmaceutical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/326,180 external-priority patent/US6242421B1/en
Application filed by Individual filed Critical Individual
Publication of CA2309395A1 publication Critical patent/CA2309395A1/fr
Abandoned legal-status Critical Current

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002309395A 1999-06-04 2000-05-24 Methodes de prevention et de traitement de la maladie d'alzheimer Abandoned CA2309395A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/326,180 1999-06-04
US09/326,180 US6242421B1 (en) 1997-11-06 1999-06-04 Methods for preventing and treating Alzheimer's disease

Publications (1)

Publication Number Publication Date
CA2309395A1 true CA2309395A1 (fr) 2000-12-04

Family

ID=23271130

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002309395A Abandoned CA2309395A1 (fr) 1999-06-04 2000-05-24 Methodes de prevention et de traitement de la maladie d'alzheimer

Country Status (1)

Country Link
CA (1) CA2309395A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102401A1 (fr) * 2001-04-30 2002-12-27 Zentaris Gmbh Traitement de la demence et de maladies neurodegeneratives par des doses intermediaires d'antagonistes de luteoluberine
WO2008077027A2 (fr) * 2006-12-18 2008-06-26 Case Western Reserve University Traitement de troubles cognitifs post-ménopausiques ou post-hystérectomie
KR100878137B1 (ko) * 2002-12-17 2009-01-14 엠디알엔에이, 인코포레이티드 Ｙ2 수용체-결합 펩티드들의 강화된 점막 전달용 혼합물과방법 및 비만 예방과 치료를 위한 방법
WO2009046877A2 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046835A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Utilisation de goséréline et d'amyline en tant qu'agents thérapeutiques

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102401A1 (fr) * 2001-04-30 2002-12-27 Zentaris Gmbh Traitement de la demence et de maladies neurodegeneratives par des doses intermediaires d'antagonistes de luteoluberine
US7288517B2 (en) 2001-04-30 2007-10-30 Aeterna Zentaris Gmbh Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
KR100878137B1 (ko) * 2002-12-17 2009-01-14 엠디알엔에이, 인코포레이티드 Ｙ2 수용체-결합 펩티드들의 강화된 점막 전달용 혼합물과방법 및 비만 예방과 치료를 위한 방법
WO2008077027A2 (fr) * 2006-12-18 2008-06-26 Case Western Reserve University Traitement de troubles cognitifs post-ménopausiques ou post-hystérectomie
WO2008077027A3 (fr) * 2006-12-18 2008-10-16 Univ Case Western Reserve Traitement de troubles cognitifs post-ménopausiques ou post-hystérectomie
WO2009046877A2 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046835A1 (fr) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Utilisation de goséréline et d'amyline en tant qu'agents thérapeutiques
WO2009046877A3 (fr) * 2007-09-11 2009-05-28 Mondobiotech Lab Ag Utilisation d'un peptide en tant qu'agent thérapeutique

Similar Documents

Publication Publication Date Title
US6242421B1 (en) Methods for preventing and treating Alzheimer's disease
Milner et al. Experience with human growth hormone in Great Britain: the report of the MRC Working Party
Pickar et al. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients
Leigh et al. Motor neuron disease
EA021303B1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
US9867816B2 (en) PPARγ agonists for treatment of multiple sclerosis
US12138254B2 (en) Chronic nightly dosing of lasmiditan for migraine prevention
US20230096920A1 (en) Treatment of demyelinating diseases
AU2024201099A1 (en) Treatment and prevention of Alzheimer's Disease (AD)
Evoli et al. A practical guide to the recognition and management of myasthenia gravis
US20190276560A1 (en) Composition and method for treating alzheimer's disease
US10736894B2 (en) Methods of treating developmental syndromes with PDE10A inhibitors
CA2309395A1 (fr) Methodes de prevention et de traitement de la maladie d'alzheimer
CN106659738B (zh) 阿尔茨海默病(ad)的治疗和预防
US20210023074A1 (en) Treatment of demyelinating diseases
JP6416213B2 (ja) 気分障害患者の治療のためのナルメフェン
US20140128412A1 (en) Combination of an antipsychotic and an anti-inflammatory agent
Wolkowitz et al. Antiglucocorticoid medication effects on specific depressive symptoms
Shea From the neurobiologic basis of alcohol dependency to pharmacologic treatment strategies: bridging the knowledge gap
Cutler et al. Alzheimer's disease: clinical, neuropathologic, neuropsychologic, and brain metabolic findings
Viegas et al. The pathogenesis of myasthenic syndromes: A practical guide to diagnosis and management
Porru et al. Explorative study on the use of omalizumab in patients suffering from interstitial cystitis/bladder pain syndrome
Schroeder et al. Reduced cerebrospinal fluid estradiol levels are associated with early onset and increased β-amyloid levels in Alzheimers disease
Wilson et al. A double‐blind dose‐determination study with flutroline: A new neuroleptic

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20140526